TABLE 1.
Comparison of HPV detection results in samples collected in liquid-based medium and solid carrier devices among CVT participantsa
| Participant group | Results by collection method |
% Positive |
Agreement |
Kappa (95% CI) | Pc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PC+/FTA+ | PC−/FTA+ | PC+/FTA− | PC−/FTA− | Total | FTA | PC | Overall | Among positives | |||
| All visits | |||||||||||
| Any HPV | 141 | 33 | 5 | 140 | 319 | 54.5 | 45.8 | 0.88 | 0.79 | 0.76 (0.69–0.83) | <0.001 |
| Carcinogenic HPVb | 78 | 21 | 6 | 214 | 319 | 31.0 | 26.3 | 0.92 | 0.74 | 0.79 (0.72–0.87) | 0.006 |
| Colposcopy visits | |||||||||||
| Any HPV | 60 | 11 | 3 | 27 | 101 | 70.3 | 62.4 | 0.86 | 0.81 | 0.69 (0.54–0.84) | 0.057 |
| Carcinogenic HPV | 37 | 10 | 5 | 49 | 101 | 46.5 | 41.6 | 0.85 | 0.71 | 0.70 (0.56–0.84) | 0.302 |
| Regular screening visits | |||||||||||
| Any HPV | 81 | 22 | 2 | 113 | 218 | 47.2 | 38.1 | 0.89 | 0.77 | 0.78 (0.69–0.86) | <0.001 |
| Carcinogenic HPV | 41 | 11 | 1 | 165 | 218 | 23.9 | 19.3 | 0.94 | 0.77 | 0.84 (0.75–0.93) | 0.006 |
a
PC, PreservCyt, liquid-based medium; FTA, solid carrier device.
b
That is, HPV16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -66, and -68/73.
c
Calculated by using the exact McNemar χ2 test.